Laporte J R, Porta M, Capella D
Br J Clin Pharmacol. 1983 Sep;16(3):301-4. doi: 10.1111/j.1365-2125.1983.tb02165.x.
To evaluate the quality of the consumption of medicines in Spain, its potential efficacy, and its evolution during the last years, an assessment of the 'intrinsic value' of the most sold pharmaceutical specialities (amounting to more than 50% of total pharmaceutical market) was carried out. A panel of five clinical pharmacologist classified medicines, according to their intrinsic value, in four groups: (i) 'high value' (41% of analyzed medicines in 1980); (ii) 'relative value' (12% in 1980); (iii) 'doubtful value' (3%); (iv) 'no value' (23%), and (v) 'unacceptable value' (21%). Drugs were also classified according to their expected potential of use; and three groups were formed: (i) 'high' (32%); (ii) 'relatively high' (14%), and (iii) 'reduced' (10%). A fourth group of 'not applicable' (44%) in this classification was formed with pharmaceuticals considered unvaluable or unacceptable in the first classification. The results of this study suggest that this kind of analysis may be a useful tool to evaluate the efficacy of drugs in the community, and to identify priorities and guidelines in the selection of drugs in each country.
为评估西班牙药品消费的质量、其潜在疗效以及过去几年的演变情况,对最畅销药品(占药品市场总额50%以上)的“内在价值”进行了评估。由五名临床药理学家组成的小组根据药品的内在价值将其分为四类:(i)“高价值”(1980年分析药品中的41%);(ii)“相对价值”(1980年为12%);(iii)“可疑价值”(3%);(iv)“无价值”(23%),以及(v)“不可接受价值”(21%)。药品还根据其预期使用潜力进行分类;分为三类:(i)“高”(32%);(ii)“相对较高”(14%),以及(iii)“低”(10%)。在该分类中,第四类“不适用”(44%)由在第一种分类中被认为无价值或不可接受的药品组成。这项研究的结果表明,这种分析可能是评估社区中药物疗效以及确定每个国家药物选择的优先事项和指导方针的有用工具。